However, with the goal of clinical application, we must not forget that TG2, despite its dysregulation in cancer, has ubiquitous tissue distribution in normal cells, so it will be important to direct inhibition against specific targets exclusive to cancer cells, in order to develop delivery systems aimed at obtaining an effective selective treatment. The gene discussed is TGM2; the disease is cancer.